TG Therapeutics, Inc.

TGTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001001316

A

strongest fifth of 369 graded peers in healthcare

rank 37 of 369; percentile 9.8; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull




Scoreboard	
Profitability	C/D percentile 61.6
Solvency	B percentile 27.7
Growth and financing	A percentile 11.4
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.1B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	8 of 14
Graded from	filings received through Feb 27, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$65.70 2026-11-11; market equity $9.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.6						
Gross profitability	48.5%	32.3%		24.7	365	2025-12-31
Return on invested capital	not computable	9.3%				


latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	57.5%	(6.6%)		98.4	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 27.7						
Twelve-month failure probability	0.02%	0.08%		10.6	247	2026-09-30
Altman Z double-prime	2.04	(0.35)		28.6	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.10x	2.95x		43.8	827	2025-12-31
Growth and financing, sleeve percentile 11.4						
Revenue growth, three-year compound	504.9%	10.1%		0.2	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	76.4%	2.2%		4.2	695	2025-12-31
Net share issuance, one year	1.7%	2.5%		29.7	628	2026-02-25

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
32	Alkermes plc. (ALKS)	8.4	A	
33	Si-Bone, Inc. (SIBN)	8.7	A	fortress balance sheet
34	Xtant Medical Holdings, Inc. (XTNT)	9.0	A	fortress balance sheet
35	Viemed Healthcare, Inc. (VMD)	9.2	A	
36	Globus Medical Inc. (GMED)	9.5	A	
37	TG Therapeutics, Inc. (TGTX)	9.8	A	
38	LivaNova plc (LIVN)	10.1	A	fortress balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	Niagen Bioscience, Inc. (NAGE)	10.6	A	
41	BridgeBio Pharma, Inc. (BBIO)	10.9	A	
42	Orthopediatrics Corp. (KIDS)	11.1	A	

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	60.4%	(1.9%)	81
Distance from 52-week high	0.0%	(27.8%)	94
EBIT to enterprise value	1.3%	(1.6%)	60
Free cash flow yield	(0.3%)	(1.0%)	53

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.06	0.27	19
Sales to price	0.06	0.29	19
Composite equity issuance, five years	7.2%	20.8%	35
Relative strength against the sector, log excess return	0.30	(0.19)	81

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$429.4M
Operating cash flow, four quarters	$86.3M
Months of runway	not finite
Days since last periodic filing	3 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$89.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$616.3M	2025-12-31	2026-02-27	10-K	26-006133
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$100.7M	2025-12-31	2026-02-27	10-K	26-006133
3	assets	us-gaap:Assets	$1.1B	2025-12-31	2026-02-27	10-K	26-006133
4	operating income	us-gaap:OperatingIncomeLoss	$20.6M	2023-12-31	2026-02-27	10-K	26-006133
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$13.1M	2023-12-31	2026-02-27	10-K	26-006133
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$390,000	2023-12-31	2026-02-27	10-K	26-006133
7	total debt	us-gaap:LongTermDebt	$100.4M	2023-12-31	2024-02-29	10-K	24-006144
8	book equity	us-gaap:StockholdersEquity	$160.5M	2023-12-31	2026-02-27	10-K	26-006133
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$92.9M	2023-12-31	2026-02-27	10-K	26-006133
10	total debt	us-gaap:LongTermDebt	$71.1M	2022-12-31	2023-03-01	10-K	23-002610
11	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$58.6M	2022-12-31	2023-03-01	10-K	23-002610
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$102.3M	2022-12-31	2025-03-03	10-K	25-005908
13	net income	us-gaap:NetIncomeLoss	$447.2M	2025-12-31	2026-02-27	10-K	26-006133
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$24.8M	2025-12-31	2026-02-27	10-K	26-006133
15	assets	us-gaap:Assets	$577.7M	2024-12-31	2026-02-27	10-K	26-006133
16	current assets	us-gaap:AssetsCurrent	$630.8M	2025-12-31	2026-02-27	10-K	26-006133
17	current liabilities	us-gaap:LiabilitiesCurrent	$153.8M	2025-12-31	2026-02-27	10-K	26-006133
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-02-27	10-K	26-006133
19	operating income	us-gaap:OperatingIncomeLoss	$123.3M	2025-12-31	2026-02-27	10-K	26-006133
20	book equity	us-gaap:StockholdersEquity	$648.0M	2025-12-31	2026-02-27	10-K	26-006133
21	liabilities	us-gaap:Liabilities	$415.2M	2025-12-31	2026-02-27	10-K	26-006133
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$211,000	2023-12-31	2026-02-27	10-K	26-006133
23	interest expense	us-gaap:InterestExpense	$12.6M	2023-12-31	2024-02-29	10-K	24-006144
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$329.0M	2024-12-31	2026-02-27	10-K	26-006133
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$233.7M	2023-12-31	2026-02-27	10-K	26-006133
26	revenue	us-gaap:Revenues	$2.8M	2022-12-31	2023-03-01	10-K	23-002610

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$214,000	2025-12-31	2026-02-27	10-K	26-006133
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$40.5M	2024-12-31	2026-02-27	10-K	26-006133
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$45,000	2024-12-31	2026-02-27	10-K	26-006133
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$31.4M	2023-12-31	2026-02-27	10-K	26-006133
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2026-02-27	10-K	26-006133
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$176.2M	2022-12-31	2025-03-03	10-K	25-005908
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14,000	2022-12-31	2025-03-03	10-K	25-005908
34	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$59,000	2025-12-31	2026-02-27	10-K	26-006133
35	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$107.4M	2025-12-31	2026-02-27	10-K	26-006133
36	income tax	us-gaap:IncomeTaxExpenseBenefit	-$339.8M	2025-12-31	2026-02-27	10-K	26-006133
37	current assets	us-gaap:AssetsCurrent	$566.4M	2024-12-31	2026-02-27	10-K	26-006133
38	current liabilities	us-gaap:LiabilitiesCurrent	$90.7M	2024-12-31	2026-02-27	10-K	26-006133
39	assets	us-gaap:Assets	$329.6M	2023-12-31	2025-03-03	10-K	25-005908
40	assets	us-gaap:Assets	$193.6M	2022-12-31	2024-02-29	10-K	24-006144
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	159,688,256	2026-02-25	2026-02-27	10-K	26-006133
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	157,070,575	2025-02-25	2025-03-03	10-K	25-005908

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.